UK Markets closed

AB Science S.A. (ABSCF)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
11.900.00 (0.00%)
At close: 09:30AM EDT

AB Science S.A.

3, Avenue George V
Paris 75008
France
33 1 47 20 00 14
https://www.ab-science.com

Sector(s)Healthcare
IndustryDrug Manufacturers—Specialty & Generic
Full-time employees96

Key executives

NameTitlePayExercisedYear born
Mr. Alain Moussy MBACo-Founder, Chairman, Pres, CEO, MD & Scientific Director645.57kN/AN/A
Mr. Denis GicquelDeputy CEO & Head of Pharmaceutical Devel.103.79kN/AN/A
Mr. Laurent Guy MBAChief Financial OfficerN/AN/AN/A
Mr. Christian FASSOTTEGlobal Chief Medical OfficerN/AN/AN/A
Mr. Alexis BERNARDHead of Veterinary SalesN/AN/AN/A
Ms. Catherine ARGILLIERHead of Quality AssuranceN/AN/AN/A
Mr. Harshad KULKARNIHead of StatisticsN/AN/AN/A
Mr. Antonello CERVONEHead of Data Management & IT DirectorN/AN/AN/A
Dr. Yves Grumser M.D.Head of Clinical Safety & PharmacovigilanceN/AN/AN/A
Ms. Veronique GelebartHead of Clinical Operations & Clinical Devel.N/AN/AN/A
Amounts are as of 31 December 2020, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

AB Science S.A., a clinical-stage pharmaceutical company, engages in the research, development, and marketing of protein kinase inhibitors for use in human and veterinary medicines. Its lead compound is the masitinib, a tyrosine kinase inhibitor that is in Phase III clinical trials for the treatment of prostate and pancreatic cancer, amyotrophic lateral sclerosis, multiple sclerosis, Alzheimer's, severe asthma, and mastocytosis diseases. The company also develops AB8939, synthetic microtubule destabilizer for the treatment of acute myeloid leukemia; and AB20001, which is in Phase 2 clinical trial to evaluate the safety and efficacy of masitinib combined with isoquercetin in hospitalized patients with moderate and severe COVID-19. The company markets its masitinib under the Masivet brand in Europe. AB Science S.A. was incorporated in 2001 and is headquartered in Paris, France.

Corporate governance

AB Science S.A.’s ISS governance QualityScore as of 1 May 2022 is 10. The pillar scores are Audit: 10; Board: 8; Shareholder rights: 7; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.